Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Characterized by the expression of the critical transcription factor forkhead box protein P3,
regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Although targeting the tumor metabolism is performed in cooperation with immunotherapy in
the era of precision oncology, ignorance of immune cells' metabolism has resulted in …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with
profound alterations and defects in the immune system and a prevalent dependency on the …

Microenvironmental bystander cells are essential for the progression of chronic lymphocytic
leukemia (CLL). We have discovered previously that LYN kinase promotes the formation of a …

Inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase δ (PI3Kδ) that
target the B-cell receptor (BCR) signaling pathway have revolutionized the treatment of …

Immune system-mediated tumor killing has revolutionized anti-tumor therapies, providing
long-term and durable responses in some patients. The phosphoinositide 3-kinase (PI3K) …

Background Duvelisib is the first FDA-approved oral dual inhibitor of phosphatidylinositol-3-
kinase PI3K-delta (PI3K-δ) and PI3K-gamma (PI3K-γ). Although many clinical studies …